Health1 min read

STAT+: In cancer drug development, the spotlight shifts onto Erasca’s KRAS-targeted treatment

By · Via STAT Health · Published by Everything Blog

In short

Erasca is advancing its pan-RAS candidate, designated ERAS-0015, after licensing the compound from China. Early-stage data shared via press releases have already spurred takeover speculation among investors noting the sharp valuation gap with Revolution Medicines. Ahead of an upcoming medical conference, CEO Jonathan Lim outlined specific efficacy benchmarks that would separate the drug from existing options. Achieving an overall response rate near 40% in advanced pancreatic cancer is seen as a key differentiator.

Key points

  • Investor speculation over a potential takeover is rising due to the significant valuation…: Investor speculation over a potential takeover is rising due to the significant valuation gap between Erasca and Revolution Medicines.
  • Chief Executive Officer Jonathan Lim identified an overall response rate near 40% in seco…: Chief Executive Officer Jonathan Lim identified an overall response rate near 40% in second line-plus pancreatic cancer as a critical milestone.
  • Upcoming presentations in Barcelona will provide a vital test for early clinical claims p…: Upcoming presentations in Barcelona will provide a vital test for early clinical claims previously limited to press releases.

Sources checked by our analysis pipeline: 1

This story first appeared in Adam’s Biotech Scorecard, a STAT newsletter. Sign up here to get it delivered to your inbox. And subscribe to STAT+ to get an unabridged version, with exclusive content.

Erasca’s pitch is straightforward: The U.S.-based biotech says it went to China and found a more potent, better-tolerated pan-RAS inhibitor than Revolution Medicines’ Rasonque. To date, Erasca has backed up its claim with scant data from an early-stage study disseminated via press releases. The story might be true, it might not be, but for now that’s less important to investors than Erasca’s $5 billion market value, which is a fraction of the $35 billion carried by Revolution Medicines. The valuation disparity makes sense given Revolution’s lead, but it also stokes speculation that Erasca could be an attractive takeover target.

On Friday, the company is presenting another slug of data on its drug, called ERAS-0015, at the EORTC-NCI-AACR “Triple” meeting in Barcelona. Erasca knows what it’s presenting already, obviously, so without breaking the meeting’s embargo policy, CEO Jonathan Lim has been signaling to investors at investment banking conferences…

Health